Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
about
Pheochromocytoma in Urologic PracticeSunitinib for refractory malignant pheochromocytoma: two case reports.Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paragangliomaAnti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.Mitochondrial Deficiencies in the Predisposition to ParagangliomaVandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.Study of microvessel density and the expression of vascular endothelial growth factors in adrenal gland pheochromocytomas.Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatmentTyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas.A Case of Malignant Pheochromocytoma Presenting 7 Years After the Initial Surgery.Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.Diagnosis and management of pheochromocytoma: a practical guide to clinicians.Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature.Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.Long clinical benefit achieved in two patients with malignant paraganglioma treated by metronomic cyclophosphamide.Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.Progress in Endocrine Neoplasia.Giant malignant pheochromocytoma with palpable rib metastases.No difference in phenotype of the main Dutch SDHD founder mutations.Systemic therapies for malignant pheochromocytoma and paraganglioma can exacerbate hypertension.New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.The adrenal medulla and extra-adrenal paraganglia: then and now.Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature.Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017)
P2860
Q30365937-3D196ECD-4B6C-471F-9253-00A3C9A68314Q33413239-F90EC895-D155-4501-81FC-4920A9AFE835Q33569980-F15B19E5-44E2-4099-951F-1C6FDB494B0FQ33638286-414A1BB6-5DB6-48F7-8550-C59E5053A389Q33844924-A736911D-EBAB-4C7C-ACF7-6FA0628ABD16Q34131012-6EABB61C-6E50-4E33-861D-FD6E165A57C5Q34206444-ADE34894-4443-4458-AC5D-F3934BB5B9F7Q34410500-673822C3-0C53-48D7-9A3F-A06BD259852DQ37159039-35482754-B9EE-4ECC-B531-34CE74206016Q37470890-58DEFC47-70B1-4076-AEE4-D3CBDEB8B97EQ37698853-AA023177-4D04-4F15-B27E-34AB553CEA1AQ37725493-3A7D1EA1-7298-4D9F-8548-65F19A8D9CCFQ38106904-FFC0722F-645E-4720-AF20-B455ED248DFAQ38208963-5ED2E046-D5F9-49D9-9889-45321EA0ECE3Q38240032-DA33DA8C-5B25-4557-A2EF-83B41DBDD6F0Q38241797-20265F0D-5FDB-407A-9CE4-6EBF83E2FCD0Q38266745-C0FADEA3-B1D2-4D5D-B18F-63178CD7BF0BQ39011468-8ACD3EDB-1B34-462A-A884-DC2626661E4CQ39084619-D00359E0-6927-471B-9BD2-285CDC86FFADQ39152232-11D95D6B-D58F-4F23-9666-AB7D5B89D44EQ42285779-699492F5-73C0-460D-A07C-471564933FBEQ42809349-4F2ACFA9-0A85-4EFD-85EB-39E8CF308C66Q45204437-3E2F42D5-9E03-4749-AF88-6AFCCCA54B94Q45900034-5F3777D4-EAD8-4F57-B3A8-EBE6FF6CB3E8Q47934716-6139991C-AE43-49C9-A8E8-0AC6125336DCQ48110909-20C0DA1B-B617-44B0-B33D-13B53C0AAF40Q51397534-BBED7B9E-C786-4152-B89E-2E5F9DE22594Q54976476-452998E5-AAF5-4CEB-9CF7-4D4F7720BA57Q54987382-1B376B32-BB95-4076-B77D-059A4A586A52Q54998061-22633364-685A-4136-9953-200EDF440E98Q57652261-BAA78DF5-8C9E-461D-9AC1-C73BAC5DBAF9
P2860
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Treatment with sunitinib for p ...... nd sympathetic paragangliomas.
@en
type
label
Treatment with sunitinib for p ...... nd sympathetic paragangliomas.
@en
prefLabel
Treatment with sunitinib for p ...... nd sympathetic paragangliomas.
@en
P2093
P2860
P356
P1476
Treatment with sunitinib for p ...... and sympathetic paragangliomas
@en
P2093
Abir Al Ghuzlan
Camilo Jimenez
Caroline Caramella
Cecile N Chougnet
Desirée Deandreis
Eric Baudin
J Lynn Palmer
Maria E Cabanillas
Montserrat Ayala-Ramirez
Pete Anderson
P2860
P304
P356
10.1210/JC.2012-2356
P407
P577
2012-09-10T00:00:00Z